Press Room

DDF - Global Drug Delivery & Formulation Summit 2025

Start
Monday, June 02, 2025 - 09:00
End
Wednesday, June 04, 2025 - 18:00
Location: Berlin, Germany
Booth Number: Table #16
Synthetic Sugars | Hovione

Hovione is exhibiting at DDF Berlin, a leading 3-day summit on drug delivery, formulation and device development that attracts over 400 senior pharmaceutical leaders. At this event, top-notch experts engage in discussions on the latest advancements in the industry, presenting case studies and sharing invaluable experience.

 

Do not miss our Solution Spotlight Session, on June 2 (Room 4, 10:00 - 10:30 am):

“Next generation of Excipients for Proteins: enhancing stability and reducing viscosity”  

The pharmaceutical industry continues to push the boundaries of innovation, particularly in the field of biologics, which now represents a significant and growing segment of therapeutic development. As these complex molecules become more prevalent, addressing formulation challenges such as stability and high viscosity becomes increasingly critical. Traditional excipients often fall short in meeting the unique demands of modern biologics, prompting the need for next-generation solutions. 

Novel excipients offer a promising path forward, enabling enhanced protein stability, reduced viscosity, and improved manufacturability and delivery. With regulatory frameworks beginning to recognize the importance of excipient innovation, now is a pivotal moment for industry stakeholders to explore and implement these advancements in protein therapeutics development. 

In our Solution Spotlight Session, presented by Joana Cristovão – R&D Manager – we introduce a platform of novel synthetic sugars designed to ensure more robust biopharmaceuticals. Case studies demonstrate the significant improvements these sugars provide in enhancing model proteins manufacturing processes, stability, and viscosity reduction across various applications.

Session Highlights:

  • Tackling complexity in protein therapeutics: Addressing the limitations of traditional formulations for high-concentration and complex biologics.
  • Next-gen excipients in action: Real-world data showing improved stability and manufacturability using novel excipients.

     

Speak with our experts and learn how our extensive knowledge and experience can support your project from early stages of development to commercialization.

We look forward to seeing you at DDF Berlin.

Schedule a meeting today.

 

schedule a meeting

 

 

 

 

 

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026